<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A histologically confirmed, clinically inapparent and reversible <z:hpo ids='HP_0012115'>hepatitis</z:hpo> occurred in 2 patients (1 <z:hpo ids='HP_0003765'>psoriasis</z:hpo>, 1 <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome) within the first months after introduction of <z:chebi fb="0" ids="4913">etretinate</z:chebi> therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Causes of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> other than <z:chebi fb="0" ids="4913">etretinate</z:chebi> were not found </plain></SENT>
<SENT sid="2" pm="."><plain>Reintroduction of <z:chebi fb="0" ids="4913">etretinate</z:chebi> resulted in reactivation and/or persistence of the <z:hpo ids='HP_0012115'>hepatitis</z:hpo> in both patients </plain></SENT>
<SENT sid="3" pm="."><plain>These data strongly suggest that the <z:hpo ids='HP_0012115'>hepatitis</z:hpo> in both patients was caused by <z:chebi fb="0" ids="4913">etretinate</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Later the <z:hpo ids='HP_0002671'>basal cell nevus</z:hpo> syndrome patient was given <z:chebi fb="0" ids="6067">13-cis-retinoic acid</z:chebi>, which caused no liver test disturbances during a follow-up period of 6 months </plain></SENT>
</text></document>